SBIR-STTR Award

Non-Surgical Device for Treatment of Middle Ear Effusion
Award last edited on: 1/6/11

Sponsored Program
SBIR
Awarding Agency
NIH : NIDCD
Total Award Amount
$1,024,123
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Daniel Arick

Company Information

ARISIL Inc (AKA: ARISIL Instruments Inc)

450 Clinton Street
Brooklyn, NY 11231
   (718) 624-0222
   ssilman@brooklyn.cuny.edu
   N/A
Location: Single
Congr. District: 07
County: Kings

Phase I

Contract Number: 1R43DC003613-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1998
Phase I Amount
$132,633
As an alternative to antibiotics and/or surgery for the treatment of otitis media, the investigator proposes a feasibility study using a modified Politzer device in children with persistent otitis media and effusion.

Phase II

Contract Number: 2R44DC003613-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2001
(last award dollars: 2002)
Phase II Amount
$891,490

The purpose of this study is to test the efficacy of a portable, automated, modified Politzer device for the nonsurgical management of middle-ear effusion in children (4-11 years of age). The objectives of this study are to determine whether the change in average air-bone gap and tympanometric peak pressure from the final pre-test to the post-test is greater for the experimental subjects who receive treatment with the device as compared with the control subjects. Subjects with middle-ear effusion will be randomly assigned to the experimental (n=59) and control groups (n=59). Each experimental subject will receive twice-daily treatment (administered by the guardian) with a portable, automated, modified Politzer apparatus over a period of 7 weeks. Post-testing (audiologic and otolaryngologic evaluations) will occur three weeks after the period encompassed by the treatment. The significance of this study will have far-reaching benefit in terms of a reduction of the need for surgical treatment for middle-ear efThsion . with resultant avoidance of possible adverse sequellae, and substantial reduction of cost of management from approximately $2,000 for surgical treatment to approximately $10 for nonsurgical management. PROPOSED COMMERCIAL APPLICATIONS: If the clinical trial proves to be successful, there will be national and international interest. Although the custom-made device costs $325 including product liability, when commercially produced, it will cost about $5.00.